Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

CAVA

Cava Group Inc

May 08 • 04:00PM ET

74.16

Dollar change -0.08
Percentage change -0.11	%

Consumer Cyclical • Restaurants • USA • NYSE

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VBK VXF IWP IWR IWF SCHA VCR SCHM

Index	-	P/E	634.39	EPS (ttm)	0.12	Insider Own	23.03%	Shs Outstand	113.58M	Perf Week	9.95%
Market Cap	8.45B	Forward P/E	230.16	EPS next Y	0.32	Insider Trans	-21.15%	Shs Float	87.75M	Perf Month	23.03%
Income	13.28M	PEG	19.76	EPS next Q	0.03	Inst Own	65.49%	Short Float	13.02%	Perf Quarter	44.42%
Sales	728.70M	P/S	11.60	EPS this Y	13.34%	Inst Trans	-	Short Ratio	4.45	Perf Half Y	116.97%
Book/sh	5.03	P/B	14.76	EPS next Y	35.37%	ROA	1.55%	Short Interest	11.43M	Perf Year	-
Cash/sh	2.92	P/C	25.43	EPS next 5Y	32.10%	ROE	3.39%	52W Range	29.05 - 77.14	Perf YTD	72.55%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	1.52%	52W High	-3.86%	Beta	-
Dividend TTM	-	Quick Ratio	3.20	Sales past 5Y	20.99%	Gross Margin	18.24%	52W Low	155.28%	ATR (14)	3.66
Dividend Ex-Date	-	Current Ratio	3.25	EPS Y/Y TTM	122.51%	Oper. Margin	4.31%	RSI (14)	65.36	Volatility	4.75% 5.51%
Employees	8460	Debt/Eq	0.59	Sales Y/Y TTM	29.17%	Profit Margin	1.82%	Recom	1.81	Target Price	65.49
Option/Short	Yes / Yes	LT Debt/Eq	0.53	EPS Q/Q	110.85%	Payout	0.00%	Rel Volume	0.46	Prev Close	74.24
Sales Surprise	1.67%	EPS Surprise	412.82%	Sales Q/Q	36.35%	Earnings	Feb 27 BMO	Avg Volume	2.57M	Price	74.16
SMA20	12.96%	SMA50	14.94%	SMA200	58.73%	Trades		Volume	1,176,519	Change	-0.11%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-15-24	Initiated	Barclays	Equal Weight	$58
Apr-10-24	Upgrade	Argus	Hold → Buy	$70
Jan-29-24	Initiated	Argus	Hold
Dec-21-23	Upgrade	Wedbush	Neutral → Outperform	$35 → $48
Dec-13-23	Initiated	TD Cowen	Outperform	$46
Nov-17-23	Initiated	Raymond James	Mkt Perform
Oct-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$45 → $41
Oct-11-23	Initiated	Wedbush	Neutral	$33
Sep-15-23	Initiated	Loop Capital	Hold	$40
Jul-10-23	Initiated	William Blair	Outperform
Jul-10-23	Initiated	Stifel	Buy	$48
Jul-10-23	Initiated	Robert W. Baird	Outperform	$50
Jul-10-23	Initiated	Piper Sandler	Overweight	$45
Jul-10-23	Initiated	Morgan Stanley	Equal-Weight	$43
Jul-10-23	Initiated	JP Morgan	Overweight	$45
Jul-10-23	Initiated	Jefferies	Buy	$48
Jul-10-23	Initiated	Citigroup	Neutral	$42

Show Previous Ratings

Today 12:08AM	CAVA Group (NYSE:CAVA): Investors Appetite for the Salad Chain Is Growing (TipRanks)
May-08-24 08:48AM	3 Restaurant Stocks That Want to Be the Next Chipotle (Barrons.com)
08:48AM	3 Restaurant Stocks That Are Vying to Be the Next Chipotle (Barrons.com)
03:30AM	Fast-Casual Restaurants Want to Be the Next Chipotle. These 3 Stand Out. (Barrons.com)
May-07-24 05:50PM	Cava Group (CAVA) Stock Sinks As Market Gains: Here's Why (Zacks)
04:30PM	Loading…
04:30PM	CAVA to Announce First Quarter 2024 Financial Results on May 28, 2024 (Business Wire)
04:17PM	Nvidia Targets 'Perfect' Breakout And 473% Growth (Investor's Business Daily)
May-05-24 05:30AM	Consumers Fed Up With Rising Food Costs Are Ditching Big Brands (The Wall Street Journal)
05:30AM	Consumers Fed Up With Food Costs Are Ditching Big Brands (The Wall Street Journal)
May-04-24 06:47AM	Stock Market Crash Warning: Don't Get Caught Holding These 3 Stocks (InvestorPlace)
May-02-24 09:30AM	Is It Worth Investing in Cava (CAVA) Based on Wall Street's Bullish Views? (Zacks)
09:25AM	Planting Hope (MYLK) Announces Receipt of Management Cease Trade Order (MTCO) (ACCESSWIRE)
Apr-30-24 05:50PM	Why the Market Dipped But Cava Group (CAVA) Gained Today (Zacks)
04:10PM	Breakout Watch: Nvidia, Broadcom Lead Top Stocks Setting Up (Investor's Business Daily)
05:15AM	Forget Starbucks: Buy This Unstoppable Growth Stock Instead (Motley Fool)
09:40AM	Loading…
Apr-29-24 09:40AM	Are Retail-Wholesale Stocks Lagging CAVA Group, Inc. (CAVA) This Year? (Zacks)
Apr-27-24 07:30AM	Where Will Cava Stock Be in 3 Years? (Motley Fool)
Apr-26-24 09:00PM	Planting Hope (MYLK) Announces Debt Reorganization and Update to Private Placement (ACCESSWIRE) +10.50%
05:20PM	Cava, IBD Stock Of The Day, Surges Past Buy Point As Restaurants Come In Hot (Investor's Business Daily)
03:42PM	Market Chatter: Cava Group Opens Location in Chicago With Expansion Plans in Midwest (MT Newswires)
07:45AM	The Planting Hope Company Inc. Announces Application for Voluntary MCTO (ACCESSWIRE)
Apr-25-24 09:00AM	CAVA Enters the Midwest with its First Chicago Restaurant (Business Wire)
Apr-24-24 05:50PM	Cava Group (CAVA) Stock Dips While Market Gains: Key Facts (Zacks)
05:45AM	Forget Chipotle, Check Out This Up-and-Coming Fast Casual Restaurant Entrant (Motley Fool)
Apr-22-24 02:15PM	Cava Just Made a Move That Supports Its Ambitious Growth Plans Through the End of the Decade (Motley Fool)
10:00AM	Is There Reason for Alarm as Cava Group Investors Sell? (GuruFocus.com)
09:45AM	2 Restaurant Stocks to Buy and Hold for Great Long-Term Potential (Motley Fool)
Apr-19-24 10:03AM	Nvidia, Broadcom Cling To 'Perfect' Status In Damaged Market (Investor's Business Daily)
Apr-18-24 05:50PM	Cava Group (CAVA) Stock Moves -0.1%: What You Should Know (Zacks)
10:55AM	Jim Cramer's New Picks: 10 Stocks to Buy (Insider Monkey)
07:37AM	Loading…
Apr-17-24 07:37AM	3 Must-Know Facts About Cava, Before You Buy the Stock (Motley Fool)
Apr-13-24 12:40PM	Could Cava Be the Next Chipotle? 3 Ways the Companies Are Similar. (Motley Fool)
Apr-12-24 09:30AM	Is Cava (CAVA) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
Apr-11-24 02:23PM	Popping Again, Nvidia Remains On List Of 16 'Perfect' Stocks (Investor's Business Daily)
10:18AM	Despite Hiccups, Nvidia Remains On List Of 16 'Perfect' Stocks (Investor's Business Daily)
09:40AM	Is CAVA Group, Inc. (CAVA) Stock Outpacing Its Retail-Wholesale Peers This Year? (Zacks)
09:00AM	Best Stock to Buy Right Now: Cava vs. Dutch Bros (Motley Fool)
05:10AM	1 Wall Street Analyst Thinks Cava Stock Is Going to $70. Is It a Buy? (Motley Fool)
Apr-09-24 05:45AM	2 Stocks That Could Be Easy Wealth Builders (Motley Fool) -7.18%
Apr-07-24 02:00PM	Cava Is Slowing Down. Here's Why That's Probably a Good Thing for Investors. (Motley Fool)
Apr-05-24 06:46AM	Is Cava Group Stock Still a Hot Buy After Rallying 60% This Year? (Motley Fool)
Apr-04-24 04:19PM	Nvidia On List Of 17 'Perfect' Stocks. Will The Market Scar Them? (Investor's Business Daily) -5.15%
11:36AM	Nvidia, Netflix And This Hot IPO Join List Of 17 'Perfect' Stocks (Investor's Business Daily)
09:35AM	Cava Group (CAVA) Just Overtook the 20-Day Moving Average (Zacks)
Apr-03-24 09:15AM	Is It Too Late to Buy Cava Stock? (Motley Fool)
Apr-02-24 11:24AM	CAVA Launches Its First Nationwide Search for the Best Guest Custom Bowl (Business Wire)
07:45AM	Planting Hope (MYLK) Announces New Private Placement and Signs Memo of Understanding for Equity Investment and Credit Facility (ACCESSWIRE)
Mar-30-24 09:30AM	2 Stocks That Could Create Lasting Generational Wealth (Motley Fool)
Mar-28-24 07:01PM	Director Theodoros Xenohristos Sells Shares of Cava Group Inc (CAVA) (GuruFocus.com)
Mar-25-24 07:01PM	International Artal Sells 2,000,000 Shares of Cava Group Inc (CAVA) (GuruFocus.com)
Mar-24-24 08:30AM	Q&A: Chipotle CEO dishes on big portion sizes, AI, and top leadership advice (Yahoo Finance)
Mar-23-24 08:00AM	3 Incredible Growth Stocks That Could Skyrocket This Year (Motley Fool)
Mar-22-24 02:16PM	This IPO Leader You've Never Heard Of Just Popped Into Buy Range (Investor's Business Daily)
02:16PM	Four Reasons This Mexican IPO Should Be On Your Radar Right Now (Investor's Business Daily)
10:23AM	4 Reasons This Mexican IPO Should Be On Your Radar Right Now (Investor's Business Daily)
10:00AM	Can Cava Stock Make You a Millionaire One Day? (Motley Fool)
09:25AM	Planting Hope Announces Extension of Non-Brokered Private Placement (ACCESSWIRE)
07:30AM	2 Reasons Cava Could Be a Standout Stock in 2024 and 2 Reasons It Could Sink (Motley Fool)
Mar-21-24 04:30PM	3 Stocks That Could Crush the Market in 2024 (InvestorPlace)
08:00AM	4 Reasons To Take A 'Hard' Look At This Mexican IPO. Watch No. 2. (Investor's Business Daily)
Mar-19-24 07:45AM	Planting Hope Engages Independent Trading Group as Market Maker (ACCESSWIRE)
Mar-18-24 08:28AM	Insiders are Selling These 10 Stocks in 2024 (Insider Monkey)
Mar-15-24 04:06PM	Sushi Chain Joins Cava, Chipotle Among Restaurant Stocks On A Roll (Investor's Business Daily)
Mar-14-24 04:38PM	Sushi Chain On A Roll, Ready To Serve Up 156% Growth (Investor's Business Daily)
Mar-12-24 09:45AM	I Wouldn't Touch This Stock With a 10-Foot Pole. Here's What I'd Buy Instead. (Motley Fool)
Mar-09-24 08:00AM	3 Magnificent Stocks That Could Help You Become a Millionaire (Motley Fool)
Mar-07-24 04:30PM	CAVA to Participate in J.P. Morgan Gaming, Lodging, Restaurant and Leisure Management Access Forum (Business Wire)
07:17AM	Why Cava Stock Jumped 25% in February (Motley Fool)
Mar-04-24 04:09PM	Cava Stock: Buy, Sell, or Hold? (Motley Fool)
03:57PM	2023 IPOs: Why Cava is a hidden gem (Yahoo Finance Video)
Mar-03-24 10:41AM	Can Cava Become the Next Chipotle? (Motley Fool)
Mar-02-24 01:00PM	3 Promising Stocks to Buy With 50% Upside Potential (InvestorPlace)
Feb-29-24 11:32PM	Director, 10% Owner International Artal Sells 3,500,000 Shares of Cava Group Inc (CAVA) (GuruFocus.com)
06:12PM	Cava has more white space ahead after its stock sailed past all-time high: CEO (Yahoo Finance)
04:07PM	Celsius Snafu Gave a Sneak-Peek to Rally-Fueling Earnings Report (Bloomberg)
01:41PM	Cava CEO talks expansion plans, aims for 1,000 locations by 2032 (Yahoo Finance Video)
Feb-28-24 10:04AM	CAVA Group, Inc. (NYSE:CAVA) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:35AM	Cava Group (CAVA) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Feb-27-24 05:15PM	Cava Stock Jumps 12% on Earnings Beat (Barrons.com) +12.20%
04:45PM	Cava Earnings Come In Early And Hot. The Restaurant IPO Is Jumping. (Investor's Business Daily)
04:42PM	Cava beats Q4 estimates as 'strong traffic' drives growth (Yahoo Finance Video)
03:35PM	Why Cava Stock Hit a New All-Time High Today (Motley Fool)
01:45PM	Cava Group (CAVA) Q4 2023 Earnings Call Transcript (Motley Fool)
11:14AM	Cava stock up on jump in Q4 same-store sales (Yahoo Finance Video)
10:45AM	Cava Stock Climbs After Company Reports Fourth-Quarter Profit (The Wall Street Journal)
06:32AM	Cava Group Inc (CAVA) Reports Robust Fiscal 2023 Results with Significant Revenue and Profit Growth (GuruFocus.com)
Feb-26-24 07:25PM	CAVA Group Reports Fourth Quarter and Full Year Fiscal 2023 Results (Business Wire)
Feb-09-24 03:55PM	Planting Hope Announces Extension of Non-Brokered Private Placement (ACCESSWIRE)
Feb-08-24 07:45AM	Planting Hope Accelerates Foodservice Strategy and Profitability Drive with Two New Board Directors and Chief Financial Officer (ACCESSWIRE)
Feb-06-24 04:30PM	CAVA to Announce Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire)
07:45AM	Planting Hope Announces Distribution of Hope and Sesame(R) Barista Blend Sesamemilk in Costco Warehouse Stores (ACCESSWIRE)
Feb-05-24 10:36AM	Here's What to Expect From CAVA Group's (CAVA) Q4 Earnings (Zacks)
Feb-02-24 04:29PM	Cava Stock: This Restaurant Leader Is Breaking Out Past A Buy Point (Investor's Business Daily)
09:40AM	Is CAVA Group, Inc. (CAVA) Outperforming Other Retail-Wholesale Stocks This Year? (Zacks)
Jan-29-24 10:35AM	Palo Alto downgraded, Dollar Tree upgraded: Wall Street's top analyst calls (The Fly)
Jan-19-24 08:12PM	Planting Hope Announces Non-Brokered Private Placement (ACCESSWIRE)
Jan-14-24 08:45AM	Where Will Cava Stock Be in 5 Years? (Motley Fool)
Jan-13-24 05:02AM	51% of Americans Retire at Age 61 or Earlier. These 2 Stocks Could Get You There Sooner. (Motley Fool)
Jan-12-24 08:30PM	Planting Hope Cancels Options Grants (ACCESSWIRE)
Jan-11-24 04:41PM	Panera Bread founder Ron Shaich: Trailblazing his way through fast casual (Yahoo Finance)

Cava Group, Inc. is a holding company, which engages in the operation of restaurants. It operates through the following segments: CAVA, Zoes Kitchen, and Other. The CAVA segment represents the financial results of all CAVA restaurants. The Zoes Kitchen segment focuses on the financial results of all Zoes Kitchen locations. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Xenohristos Theodoros	Director	Mar 26 '24	Sale	68.29	47,239	3,225,851	526,521	Mar 28 04:01 PM
Artal International S.C.A.	Director	Mar 21 '24	Sale	66.25	2,000,000	132,500,000	26,507,990	Mar 25 04:15 PM
SHAICH RONALD M	Former 10% Owner	Mar 04 '24	Sale	57.20	1,500,000	85,800,000	4,457,634	Mar 06 04:00 PM
Xenohristos Theodoros	Director	Feb 29 '24	Sale	58.51	4,500	263,295	0	Mar 04 04:01 PM
Artal International S.C.A.	Director	Feb 27 '24	Sale	53.60	3,500,000	187,600,000	28,507,990	Feb 29 04:16 PM
Schulman Brett	CEO and President	Dec 06 '23	Option Exercise	1.28	10,000	12,800	1,002,421	Dec 08 04:01 PM
Amouyal Philippe	Director	Nov 17 '23	Buy	33.18	10,000	331,800	15,000	Nov 21 04:00 PM
Xenohristos Theodoros	Director	Jun 20 '23	Buy	22.00	4,500	99,000	4,500	Jun 22 04:33 PM
Tolivar Tricia K.	Chief Financial Officer	Jun 20 '23	Buy	22.00	2,500	55,000	2,500	Jun 22 04:31 PM
Bertram Kenneth Robert	CLO & Secretary	Jun 20 '23	Buy	22.00	2,295	50,490	1,500	Jun 22 04:32 PM
Somers Jennifer	Chief Operations Officer	Jun 20 '23	Buy	22.00	300	6,600	300	Jun 22 04:31 PM

Open in Screener

LXRX

Lexicon Pharmaceuticals Inc

May 08 • 04:00PM ET

1.77

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

LXRX Lexicon Pharmaceuticals Inc daily Stock Chart

Held by: VTI VXF IWM SCHA VTWO IWN IWO ITOT IWC VFMO

Index	RUT	P/E	-	EPS (ttm)	-0.82	Insider Own	2.74%	Shs Outstand	244.92M	Perf Week	7.27%
Market Cap	435.84M	Forward P/E	-	EPS next Y	-0.64	Insider Trans	1.50%	Shs Float	239.50M	Perf Month	-14.49%
Income	-192.07M	PEG	-	EPS next Q	-0.18	Inst Own	73.56%	Short Float	8.40%	Perf Quarter	-17.67%
Sales	2.31M	P/S	188.68	EPS this Y	10.81%	Inst Trans	18.05%	Short Ratio	4.43	Perf Half Y	37.21%
Book/sh	1.17	P/B	1.51	EPS next Y	9.77%	ROA	-66.24%	Short Interest	20.12M	Perf Year	-45.71%
Cash/sh	1.44	P/C	1.23	EPS next 5Y	-	ROE	-101.92%	52W Range	0.92 - 3.73	Perf YTD	15.69%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.80%	ROI	-48.77%	52W High	-52.55%	Beta	1.39
Dividend TTM	-	Quick Ratio	15.56	Sales past 5Y	186.21%	Gross Margin	69.62%	52W Low	92.39%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	15.58	EPS Y/Y TTM	-30.42%	Oper. Margin	-8045.91%	RSI (14)	47.15	Volatility	8.93% 8.09%
Employees	285	Debt/Eq	0.37	Sales Y/Y TTM	1734.13%	Profit Margin	-8311.12%	Recom	1.80	Target Price	5.25
Option/Short	Yes / Yes	LT Debt/Eq	0.36	EPS Q/Q	-16.69%	Payout	-	Rel Volume	0.35	Prev Close	1.77
Sales Surprise	-21.43%	EPS Surprise	-11.11%	Sales Q/Q	4608.33%	Earnings	May 02 AMC	Avg Volume	4.54M	Price	1.77
SMA20	3.16%	SMA50	-14.86%	SMA200	5.90%	Trades		Volume	1,609,687	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Initiated	Leerink Partners	Outperform	$5
Mar-07-23	Initiated	Jefferies	Hold	$3
Aug-12-22	Initiated	Piper Sandler	Overweight	$10
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$7
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral	$2 → $8
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral	$3 → $4
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy	$3
Jul-29-19	Downgrade	Stifel	Buy → Hold	$10 → $4
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy	$24 → $23
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight	$10
Mar-01-17	Reiterated	Wedbush	Outperform	$33 → $38
Mar-01-17	Reiterated	H.C. Wainwright	Buy	$26 → $27
Oct-07-16	Initiated	H.C. Wainwright	Buy	$26
Aug-05-16	Reiterated	Wedbush	Outperform	$30 → $31
Aug-02-16	Initiated	Citigroup	Buy	$21

Show Previous Ratings

May-06-24 10:05AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.17%
May-03-24 07:46AM	Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
04:07AM	Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-02-24 08:59PM	LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:05PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:03PM	Loading…
06:03PM	Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ... (GuruFocus.com)
05:00PM	Lexicon: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-24 10:42AM	Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire (MT Newswires)
09:00AM	Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals (GlobeNewswire)
07:00AM	Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024 (GlobeNewswire)
Apr-18-24 08:00AM	Lexicon Pharmaceuticals to Host 2024 Investor Day (GlobeNewswire)
Apr-16-24 12:00PM	All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy (Zacks) -9.36%
Apr-03-24 08:00AM	Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.69%
Mar-25-24 09:20AM	Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo (GlobeNewswire) -6.19%
12:45PM	Loading…
Mar-13-24 12:45PM	Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin (Zacks)
Mar-12-24 08:00AM	New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease (GlobeNewswire) -10.32%
Mar-11-24 08:25AM	Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +29.49%
07:34AM	Lexicon: Q4 Earnings Snapshot (Associated Press Finance)
07:15AM	Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:05AM	Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities (GlobeNewswire)
07:00AM	Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA (GlobeNewswire)
Feb-29-24 10:00AM	Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-22-24 12:58PM	15 Hot Penny Stocks On the Move (Insider Monkey) -5.58%
Jan-31-24 05:06AM	3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts (Motley Fool) +6.25%
Jan-23-24 05:21AM	3 of the Fastest-Growing Stocks on the Planet in 2024 (Motley Fool) +15.94%
Jan-08-24 07:00AM	Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-23 05:06AM	3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street (Motley Fool) +7.63%
Dec-21-23 04:15PM	Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference (GlobeNewswire)
Nov-30-23 07:30AM	Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
07:30AM	Loading…
Nov-22-23 07:30AM	Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-15-23 01:03AM	Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc (GuruFocus.com)
Nov-12-23 02:10PM	INPEFA (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data (GlobeNewswire)
Nov-10-23 04:01PM	Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
10:53AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 09:45PM	Q3 2023 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -8.80%
07:19AM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 09:00AM	Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023 (GlobeNewswire) +5.71%
Nov-02-23 09:00AM	Data on Early Clinical Benefit for INPEFA (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023 (GlobeNewswire)
Nov-01-23 09:00AM	INPEFA (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients (GlobeNewswire) +8.06%
Oct-31-23 04:01PM	Lexicon Strengthens Management Team With Two New Executives (GlobeNewswire)
Oct-30-23 04:01PM	New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting (GlobeNewswire) +8.11%
Oct-25-23 08:45AM	Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027 (PR Newswire)
Oct-17-23 04:01PM	Data From Two Studies Demonstrating Positive Financial Impact of INPEFA (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting (GlobeNewswire) -8.09%
01:35PM	Hedge Fund and Insider Trading News: John Paulson, Ray Dalio, Starboard Value, Trian Fund Management, ExodusPoint Capital Management, JAT Capital, Lexicon Pharmaceuticals, Inc. (LXRX), Omnicom Group Inc. (OMC), and More (Insider Monkey)
Oct-13-23 11:38AM	Hedge Fund and Insider Trading News: Leon Cooperman, Ray Dalio, Bill Ackman, John Paulson, Altana Wealth Ltd., Apple Inc. (AAPL), Lexicon Pharmaceuticals Inc (LXRX), and More (Insider Monkey) +14.42%
Oct-11-23 11:13AM	Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts (Zacks)
09:00AM	Data Demonstrating Financial Impact of INPEFA (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting (GlobeNewswire)
Oct-10-23 11:25AM	Why Shares of Lexicon Pharmaceuticals Are Up Tuesday (Motley Fool) +12.00%
09:44AM	Midday movers: PepsiCo, Unity, Rivian Automotive and more (Investing.com)
03:33AM	Lexicon Pharma shares rise after Inpefa gets preferred status at Express Scripts (Investing.com)
Oct-09-23 04:01PM	INPEFA (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients (GlobeNewswire) -7.41%
08:00AM	Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer (GlobeNewswire)
Sep-28-23 09:00AM	Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 (GlobeNewswire) -9.09%
Sep-26-23 09:00AM	Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) (GlobeNewswire) +10.38%
Sep-20-23 12:28PM	15 Best Affordable Stocks To Buy Under $5 (Insider Monkey)
Sep-14-23 09:40PM	Insider Buying: Jeffrey Wade Acquires 10,000 Shares of Lexicon Pharmaceuticals Inc (LXRX) (GuruFocus.com)
Sep-07-23 04:30PM	Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference (GlobeNewswire)
09:00AM	Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Aug-21-23 09:00AM	Lexicon to Present Analyses of INPEFA (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023 (GlobeNewswire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-08-23 09:00AM	Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure (GlobeNewswire) +7.06%
Aug-04-23 09:12AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 49%, while individual investors hold 25% (Simply Wall St.)
Aug-03-23 05:15PM	Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Lexicon: Q2 Earnings Snapshot (AP Finance)
04:01PM	Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-23 04:01PM	Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023 (GlobeNewswire)
08:00AM	Lexicon Elects Diane E. Sullivan to Board of Directors (GlobeNewswire)
Jun-30-23 06:52AM	Daily Vickers Top Buyers & Sellers for 06/30/2023 (Argus Research) +5.53%
Jun-27-23 06:46AM	Daily Vickers Top Buyers & Sellers for 06/27/2023 (Argus Research)
Jun-23-23 08:45PM	Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development (GlobeNewswire)
09:24AM	Daily Vickers Top Buyers & Sellers for 06/23/2023 (Argus Research)
Jun-20-23 08:00AM	Lexicon to Present Study Results Relating to LX9211 and INPEFA (Sotagliflozin) at the American Diabetes Associations 83rd Scientific Sessions (GlobeNewswire)
Jun-15-23 05:00PM	UPDATE: Lexicon Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure (GlobeNewswire)
Jun-06-23 04:01PM	Lexicon Pharmaceuticals to Participate in the Jefferies 2023 Global Healthcare Conference (GlobeNewswire)
Jun-05-23 04:01PM	Lexicon Announces Closing of Public Offering and Concurrent Private Placement, Including Full Exercise of Options to Purchase Additional Shares (GlobeNewswire) -7.47%
Jun-04-23 07:00AM	The Word Is, 'Lexicon' Is Worth a Trade (TheStreet.com)
Jun-02-23 09:21AM	Why Lexicon Pharmaceuticals Stock Crashed This Week (Motley Fool)
Jun-01-23 11:35AM	Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More (Zacks) -17.88%
08:00AM	Lexicon Announces Pricing of $125 Million Public Offering and Concurrent Private Placement (GlobeNewswire)
May-31-23 04:01PM	Lexicon Announces Proposed Public Offering of Common Stock (GlobeNewswire) +13.79%
May-26-23 04:25PM	UPDATE 2-U.S. FDA approves Lexicon Pharma's drug for heart failure (Reuters) +9.66%
04:08PM	U.S. FDA approves Lexicon Pharma's heart failure drug (Reuters)
04:05PM	Lexicon Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure (GlobeNewswire)
May-22-23 07:33AM	Weekly biotech pulse: Sana, aTyr, Theseus to release fresh data (Investing.com) +6.64%
May-11-23 06:50AM	Wall Street's Counting on an FDA Nod for This Growth Stock to Nearly Double, but Should You? (Motley Fool)
May-10-23 04:30PM	New Analysis Finds Sotagliflozin to Be a Cost-Effective Treatment at Commonly Accepted Willingness-to-Pay Threshold in Patients with Worsening Heart Failure (GlobeNewswire)
May-04-23 10:05AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2023 Earnings Call Transcript (Insider Monkey) +12.41%
May-03-23 11:45AM	Q1 2023 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +15.13%
May-02-23 04:00PM	Lexicon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-23 04:00PM	Lexicon Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call and Webcast on May 2, 2023 (GlobeNewswire)
Apr-22-23 08:15AM	Should You Buy This Growth Stock Right Now Before It Potentially Doubles? (Motley Fool)
Apr-21-23 09:00AM	Lexicon To Present Results From LX9211 Phase 2 Trial In Postherpetic Neuralgia At The 2023 American Academy Of Neurology (AAN) Annual Meeting And The British Pain Society (BPS) 56th Annual Scientific Meeting 2023 (GlobeNewswire)
Apr-17-23 04:00PM	Lexicon Pharmaceuticals to Participate in The 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +11.62%
Mar-06-23 06:00AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-04-23 12:00PM	New Analyses of Sotagliflozin Showing Time to Clinical Benefit Presented at The American College of Cardiologys 72nd Annual Scientific Session Together With World Heart Federations World Congress of Cardiology (GlobeNewswire)
10:00AM	Lexicon Reveals INTO THE DARK Awareness Campaign About Vulnerable and Dangerous Period of Time Faced by Heart Failure Patients Following Hospitalization (GlobeNewswire)
Mar-03-23 07:07AM	Q4 2022 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +22.94%
Mar-02-23 04:00PM	Lexicon Pharmaceuticals Reports Fourth Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SOBECKI CHRISTOPHER J	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	167,055	Apr 29 04:20 PM
Swain Judith L	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	48,364	Apr 29 04:21 PM
DEBBANE RAYMOND	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	1,348,879	Apr 29 04:17 PM
LEFKOWITZ ROBERT J MD	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	48,364	Apr 29 04:18 PM
BARKER SAM L	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	87,649	Apr 29 04:17 PM
Amouyal Philippe	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	248,364	Apr 29 04:16 PM
COATS LONNEL	Chief Executive Officer	Nov 16 '23	Buy	1.05	90,000	94,797	914,359	Nov 17 04:55 PM
COATS LONNEL	Chief Executive Officer	Nov 10 '23	Buy	1.01	10,000	10,100	824,359	Nov 13 05:31 PM
DEBBANE RAYMOND	Director	Oct 12 '23	Buy	1.03	148,820	153,805	1,340,847	Oct 12 04:01 PM
DEBBANE RAYMOND	Director	Oct 11 '23	Buy	1.08	342,874	370,784	1,192,027	Oct 12 04:01 PM
DEBBANE RAYMOND	Director	Oct 10 '23	Buy	1.14	508,306	579,367	849,153	Oct 12 04:01 PM
WADE JEFFREY L	President and CFO	Sep 14 '23	Buy	1.38	10,000	13,800	264,341	Sep 14 05:05 PM
McDermott Wendy	VP, Human Resources	Aug 04 '23	Buy	1.84	6,000	11,040	28,478	Aug 07 04:13 PM
COATS LONNEL	Chief Executive Officer	Jun 29 '23	Buy	2.16	10,000	21,600	814,359	Jun 29 04:13 PM
COATS LONNEL	Chief Executive Officer	Jun 26 '23	Buy	2.18	10,000	21,792	804,359	Jun 26 04:04 PM
COATS LONNEL	Chief Executive Officer	Jun 23 '23	Buy	2.50	10,000	24,950	794,359	Jun 26 04:04 PM
McDermott Wendy	VP, Human Resources	Jun 23 '23	Buy	2.43	10,000	24,300	22,478	Jun 27 04:22 PM
COATS LONNEL	Chief Executive Officer	Jun 22 '23	Buy	2.31	40,000	92,400	784,359	Jun 22 04:01 PM
WADE JEFFREY L	President and CFO	Jun 20 '23	Buy	2.33	12,000	28,000	254,341	Jun 20 04:10 PM
Artal International S.C.A.	Director	Jun 05 '23	Buy	2.60	27,775,050	72,215,130	78,634,381	Jun 05 04:46 PM
Swain Judith L	Director	May 21 '23	Option Exercise	0.00	9,302	0	40,332	May 22 04:07 PM
NIES ALAN S	Director	May 21 '23	Option Exercise	0.00	9,302	0	41,046	May 22 04:05 PM
DEBBANE RAYMOND	Director	May 21 '23	Option Exercise	0.00	9,302	0	340,847	May 22 04:03 PM
LEFKOWITZ ROBERT J MD	Director	May 21 '23	Option Exercise	0.00	9,302	0	40,332	May 22 04:04 PM
Palantoni Frank	Director	May 21 '23	Option Exercise	0.00	9,302	0	40,332	May 22 04:06 PM
SOBECKI CHRISTOPHER J	Director	May 21 '23	Option Exercise	0.00	9,302	0	159,023	May 22 04:06 PM
Amouyal Philippe	Director	May 21 '23	Option Exercise	0.00	9,302	0	40,332	May 22 04:01 PM
BARKER SAM L	Director	May 21 '23	Option Exercise	0.00	9,302	0	79,617	May 22 04:02 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

CAVA

Cava Group Inc

LXRX

Lexicon Pharmaceuticals Inc

Upgrade your FINVIZ experience